newsfilter
← Latest News
GlobeNewswire·

NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022

Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting supporting a